A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

Inclusion Criteria: * Patients must have a histologically or cytologically confirmed cancer diagnosis for which EGFRI treatment is indicated * Initiation of topical steroids or control treatment within 3 days of initiation of cetuximab, erlotinib, panitumumab, or afatinib * Patients must be age ≥ 18 years. * Life expectancy of greater than 6 weeks * Patient able to use topical medications reliably and complete questionnaires with assistance if needed * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study. Exclusion Criteria: * Patients who have used systemic or topical steroids within 7 days of trial registration, or start systemic or topical steroids for reasons unrelated to trial during the 6-week follow up period * Patients who have used antibiotics within 7 days of trial registration, or start antibiotics for other conditions during the 6-week follow up period * History of allergic reactions to topical steroids * Patients with any rash at the time of study registration * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients using any other topical medications in the treatment areas (face, chest, or back).